Purpose We reviewed follow-up of patients treated in 19 randomized trials of adjuvant
epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent …

Luminal breast cancer, as defined by oestrogen and/or progesterone expression by
immunohistochemistry, accounts for up to 75% of all breast cancers. In this population …

Purpose To determine the risk factors for acute myeloid leukemia (AML) or myelodysplastic
syndrome (MDS) after breast cancer. Patients and Methods We conducted a case-control …

Second malignant neoplasms (SMNs) are potentially life‑threatening late sequelae of the
adjuvant therapy for breast cancer (BC). The increased risk of SMNs is associated with …

Therapy-related myeloid neoplasms (t-MN) include acute myeloid leukemias and
myelodysplastic syndromes arising in patients who have been treated with chemotherapy …

Combined chemotherapy is used for the treatment of a number of malignancies such as
breast cancer. The target of these antineoplastic agents is nuclear DNA, although it is not …

The effect of the immunomodulatory chemotherapeutic agent cyclophosphamide (CTX) on
tumor growth was investigated in primary and metastatic intracerebral and subcutaneous rat …

Abstract Background Primary non-Hodgkin lymphoma (NHL) of the breast represents 0.04–
0.5% of malignant lesions of the breast and accounts for 1.7–2.2% of extra-nodal NHL. Most …

The sensitivity of the alkaline comet assay for the evaluation of baseline and treatment-
induced DNA damage in white blood cells of breast cancer patients receiving adjuvant …

Breast cancer is the most frequent cancer among women and the leading cause of death
among middle-aged women. Early detection by mammography screening and improvement …